TFF Pharmaceuticals Announces Safety and Pharmacokinetic Data from Phase 1 Study of Niclosamide Inhalation Powder

Niclosamide Inhalation Powder Well Tolerated with No Serious Adverse Events Across All Subject Cohorts Current Data Suggests Niclosamide Inhalation Powder is a Promising Antiviral Treatment to Combat COVID-19

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.

3 COMMENTS

LEAVE A REPLY

Please enter your comment!
Please enter your name here